Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept
- 1 September 2012
- journal article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 31 (12) , 1677-1682
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanerceptClinical Rheumatology, 2009
- Successful Treatment with Etanercept of a Patient with Psoriatic Arthritis after Adalimumab-Related HepatotoxicityInternational Journal of Immunopathology and Pharmacology, 2009
- Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trialArthritis & Rheumatism, 2008
- Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.2008
- Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 2006
- Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006
- Anti–tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infectionArthritis Care & Research, 2004
- Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.2004
- Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infectionAnnals of the Rheumatic Diseases, 2003
- Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor αNew England Journal of Medicine, 2002